title: Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor.
abstract: The 5-HT3 receptor is a member of the Cys-loop family of transmitter receptors. It can function as a homopentamer (5-HT3A-only subunits) or as a heteropentamer. The 5-HT3AB receptor is the best characterized heteropentamer. This receptor differs from a homopentamer in its kinetics, voltage dependence, and single-channel conductance, but its pharmacology is similar. To understand the contribution of the 5-HT3B subunit to the binding site, we created homology models of 5-HT3AB receptors and docked 5-HT and granisetron into AB, BA, and BB interfaces. To test whether ligands bind in any or all of these interfaces, we mutated amino acids that are important for agonist and antagonist binding in the 5-HT3A subunit to their corresponding residues in the 5-HT3B subunit and vice versa. Changes in [3H]granisetron binding affinity (Kd) and 5-HT EC50 were determined using receptors expressed in HEK-293 cells and Xenopus oocytes, respectively. For all A-to-B mutant receptors, except T181N, antagonist binding was altered or eliminated. Functional studies revealed that either the receptors were nonfunctional or the EC50 values were increased. In B-to-A mutant receptors there were no changes in Kd, although EC50 values and Hill slopes, except for N170T mutant receptors, were similar to those for 5-HT3A receptors. Thus, the experimental data do not support a contribution of the 5-HT3B subunit to the binding pocket, and we conclude that both 5-HT and granisetron bind to an AA binding site in the heteromeric 5-HT3AB receptor.
authors.affiliation: Department of Chemistry, University of Warwick, Coventry, United Kingdom.
authors.forename: M
authors.initials: M
authors.lastname: Lochner
authors.forename: S C R
authors.initials: SC
authors.lastname: Lummis
mesh_terms: D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D000818:Animals; D002460:Cell Line; D017829:Granisetron / Q000378:metabolism; D006801:Humans; D008024:Ligands; D051379:Mice; D008958:Models, Molecular; D008969:Molecular Sequence Data; D050505:Mutant Proteins / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D055503:Protein Multimerization; D021122:Protein Subunits / Q000737:chemistry / Q000378:metabolism; D044406:Receptors, Serotonin, 5-HT3 / Q000737:chemistry / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D058827:Serotonin 5-HT3 Receptor Agonists; D058831:Serotonin 5-HT3 Receptor Antagonists; D040681:Structural Homology, Protein; D014981:Xenopus
chemical_list: D017829:Granisetron; D008024:Ligands; D050505:Mutant Proteins; D021122:Protein Subunits; D044406:Receptors, Serotonin, 5-HT3; D012701:Serotonin; D058827:Serotonin 5-HT3 Receptor Agonists; D058831:Serotonin 5-HT3 Receptor Antagonists
references.citation: J Clin Oncol. 2003 Jun 1;21(11):2147-55
references.pmid: 12775740
references.citation: Biotechniques. 1988 Jul-Aug;6(7):632-8
references.pmid: 3273409
references.citation: J Biol Chem. 2004 May 28;279(22):23294-301
references.pmid: 14998995
references.citation: Biophys J. 2003 Apr;84(4):2338-44
references.pmid: 12668442
references.citation: Nature. 2001 May 17;411(6835):269-76
references.pmid: 11357122
references.citation: Biochemistry. 2005 Jun 28;44(25):9140-9
references.pmid: 15966738
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12595-600
references.pmid: 16116092
references.citation: Biophys J. 2003 Mar;84(3):1720-33
references.pmid: 12609874
references.citation: Mol Pharmacol. 2005 Aug;68(2):365-71
references.pmid: 15914697
references.citation: Nature. 2003 Jul 17;424(6946):321-4
references.pmid: 12867984
references.citation: Biochemistry. 2006 Jan 31;45(4):1099-105
references.pmid: 16430206
references.citation: Trends Pharmacol Sci. 2005 Nov;26(11):587-94
references.pmid: 16194573
references.citation: J Recept Signal Transduct Res. 2003;23(2-3):255-70
references.pmid: 14626451
references.citation: Nucleic Acids Res. 1996 Feb 15;24(4):596-601
references.pmid: 8604299
references.citation: Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92
references.pmid: 3881765
references.citation: J Pharmacol Exp Ther. 2005 Jul;314(1):320-8
references.pmid: 15814570
references.citation: J Biol Chem. 2005 May 27;280(21):20476-82
references.pmid: 15781467
references.citation: J Mol Biol. 1993 Dec 5;234(3):779-815
references.pmid: 8254673
references.citation: Br J Pharmacol. 2008 Apr;153(8):1686-96
references.pmid: 18311193
references.citation: J Mol Biol. 2001 Jun 29;310(1):243-57
references.pmid: 11419950
references.citation: Neuropharmacology. 2009 Jan;56(1):2-5
references.pmid: 18655795
references.citation: Biochem Soc Trans. 2004 Jun;32(Pt3):547-52
references.pmid: 15157181
references.citation: J Biol Chem. 1999 Oct 22;274(43):30799-810
references.pmid: 10521471
references.citation: Gene. 2003 May 22;310:101-11
references.pmid: 12801637
references.citation: Biochemistry. 2002 Aug 13;41(32):10262-9
references.pmid: 12162741
references.citation: Am J Physiol. 1993 Nov;265(5 Pt 1):L421-9
references.pmid: 8238529
references.citation: J Neurochem. 2000 Jul;75(1):240-7
references.pmid: 10854267
references.citation: BMC Neurosci. 2006 Mar 29;7:27
references.pmid: 16571125
references.citation: Biophys J. 2008 Nov 1;95(9):4115-23
references.pmid: 18641081
references.citation: J Biol Chem. 2006 Mar 24;281(12):8062-71
references.pmid: 16407231
references.citation: Mol Membr Biol. 2002 Jan-Mar;19(1):11-26
references.pmid: 11989819
references.citation: Brain Res Mol Brain Res. 1999 Apr 20;67(2):221-30
references.pmid: 10216220
references.citation: Biotechniques. 1999 Apr;26(4):672-6
references.pmid: 10343904
references.citation: J Am Chem Soc. 2003 Jun 11;125(23):6850-1
references.pmid: 12783521
references.citation: Neuron. 1992 Nov;9(5):861-71
references.pmid: 1419000
references.citation: Nature. 1999 Jan 28;397(6717):359-63
references.pmid: 9950429